← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
  1. Home
  2. LGVN
  3. P/E History
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

LGVN logoLongeveron Inc. (LGVN) P/E Ratio History

Historical price-to-earnings valuation from 2026 to 2026

Current P/E
-0.7
N/A
5Y Avg P/E
N/A
PE Percentile
N/A
PEG Ratio
N/A
N/A
TTM EPS$-0.99
Price$0.85
5Y PE RangeN/A
Earnings YieldN/A

Loading P/E history...

LGVN Valuation Context

How does the current P/E compare to historical and market benchmarks?

vs. 5Y Average
-0.7vsN/A
N/A
vs. Healthcare
-0.7vs22.3
-103%
Below Sector
vs. S&P 500
-0.7vs25.1
-103%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on -21% EPS growth (1Y)

P/E Ratio Analysis

As of May 8, 2026, Longeveron Inc. (LGVN) trades at a price-to-earnings ratio of -0.7x, with a stock price of $0.85 and trailing twelve-month earnings per share of $-0.99.

Compared to the Healthcare sector median P/E of 22.3x, LGVN trades at a 103% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.

Relative to the broader market, LGVN trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our LGVN DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

LGVN P/E vs Peers

P/E ratio compared to closely matched public peers

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
BCLI logoBCLIBrainstorm Cell Therapeutics Inc.
$7M0.3Lowest-+149%Best
CELH logoCELHCelsius Holdings, Inc.
$9B137.02.93-44%
MDXG logoMDXGMiMedx Group, Inc.
$548M11.5-+14%
ICLR logoICLRICON Public Limited Company
$10B13.11.87Best+29%

Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.

See LGVN's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is LGVN Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare LGVN vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

LGVN — Frequently Asked Questions

Quick answers to the most common questions about buying LGVN stock.

Is LGVN stock overvalued or undervalued?

LGVN current P/E: -0.7x. 5-year average P/E: N/A. Percentile: N/A.

How does LGVN's valuation compare to peers?

Longeveron Inc. P/E of -0.7x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.

What is LGVN's PEG ratio?

LGVN PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.

LGVN P/E Ratio History

P/E ratio calculated as closing price divided by trailing 12-month diluted EPS at each quarter end.